



A patient's pathway: Alzheimer's Disease

We are entering an era filled with hope in the fight against Alzheimer's Disease. New therapies that target amyloid, a protein that builds up in the brain and disrupts neuron function, could help to slow down progression of early Alzheimer's Disease.



GE HealthCare is well positioned to support the patient journey with its products and solutions — from diagnosis through to therapy planning and monitoring.



Did you know

11%

About 1 in 9 people age 65 and older (11%) has Alzheimer's¹

74%

of dementia caregivers say that they are concerned about maintaining their own health since becoming a caregiver²

27%-35%

New therapies have shown to decrease the progression of early Alzheimer's Disease by 27%-35% after 18 months of treatment.^{3,4}

SOURCES

1. <https://www.alz.org/alzheimers-dementia/facts-figures>. Consulted in July 2025.
2. <https://www.alz.org/news/2024/november-national-family-caregivers-month>. Consulted in July 2025.
3. <https://www.yalemedicine.org/news/lecanemab-leqembi-new-alzheimers-drug>. Consulted in July 2025.
4. <https://www.sciencealert.com/major-alzheimers-trial-shows-new-drug-can-slow-disease-progression>. Consulted in July 2025.



GE HealthCare